Table 2.
Extracted data of included randomized controlled trials.
| Trial Name/ID Number | Experimental Arm | Control Arm | Patient Numbers | Median Follow-Up | Overall Response Rate | Median PFS | Hazard Ratio (95% CI), PFS | Median OS | Hazard Ratio (95% CI), OS |
|---|---|---|---|---|---|---|---|---|---|
| Study 119 | Idelalisib Ofatumumab | Ofatumumab | 174 vs. 87 | 16.1 vs. 5.8 months | 75.3% vs. 18.4% | 16.4 vs. 8.0 months | 0.26 (0.18 to 0.38) | NR vs NR | 0.750 (0.48 to 1.18) |
| DUO trial | Duvelisib | Ofatumumab | 160 vs. 159 | 22.4 months | 73.8% vs. 45.3% | 13.3 vs. 9.9 months | 0.52 (0.39 to 0.7) | NR vs NR | 0.99 (0.65 to 1.5) |
| RESONATE | Ibrutinib | Ofatumumab | 195 vs. 196 | 19 months | 90% vs. 25% | NR vs. 8.1 months | 0.10 (0.07 to 0.15) | NR vs NR | 0.361 (0.208 to 0.628) |
| CR102604 | Ibrutinib | Rituximab | 106 vs. 54 | 17.8 months | 67.9% vs. 7.4% | NR vs. 8.3 months | 0.18 (0.105 to 0.308) | NR vs 26.1 months | 0.446 (0.221 to 0.9) |
| HELIOS | Ibrutinib BR | BR | 289 vs. 289 | 17 months | 86% vs. 69% | NR vs. 13.3 months | 0.203 (0.15 to 0.276) | NR vs NR | 0.628 (0.385 to 1.024) |
| MURANO | Venetoclax R | BR | 194 vs. 195 | 23.8 months | 93.3% vs. 67.7% | NR vs. 17 months | 0.17 (0.12 to 0.26) | NR vs NR | 0.48 (0.25 to 0.9) |
| TUGELA | Idelalisib BR | BR | 207 vs. 209 | 14 months | 70% vs. 45% | 20.8 vs. 11.1 months | 0.33 (0.25 to 0.44) | NR vs 31.6 months | 0.62 (0.42 to 0.92) |
PFS: Progression-free survival, OS: Overall survival, B: Bendamustine, R: Rituximab, NR: Not reached, CI: Confidence interval.